Exagen Diagnostics
Helps patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions.
Launch date
Employees
Market cap
CAD70.2m
Enterprise valuation
CAD69m (Public information from Sep 2024)
Share price
$2.84 XGN
Albuquerque New Mexico (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 40.4m | 42.0m | 48.3m | 45.6m | 52.5m | 57.2m | 65.0m |
| % growth | 24 % | 4 % | 15 % | (6 %) | 15 % | 9 % | 14 % |
| EBITDA | (8.8m) | (14.2m) | (24.1m) | (39.7m) | (19.2m) | - | - |
| % EBITDA margin | (22 %) | (34 %) | (50 %) | (87 %) | (36 %) | - | - |
| Profit | (12.0m) | (16.7m) | (26.9m) | (47.4m) | (23.7m) | - | - |
| % profit margin | (30 %) | (40 %) | (56 %) | (104 %) | (45 %) | - | - |
| R&D budget | 2.2m | 3.6m | 7.2m | 9.9m | 4.9m | - | - |
| R&D % of revenue | 5 % | 9 % | 15 % | 22 % | 9 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$5.4m | Series A | ||
$7.0m | Series B | ||
| N/A | $1.0m | Early VC | |
$12.0m | Early VC | ||
$16.9m | Early VC | ||
$5.4m | Early VC | ||
| N/A | $4.9m | Early VC | |
| N/A | $1.0m | Debt | |
$5.3m | Series C | ||
| N/A | $123k | Debt | |
| N/A | $5.0m | Early VC | |
$25.0m | Debt | ||
$4.0m | Debt | ||
| N/A | $1.8m | Debt | |
| N/A | $3.0m | Debt | |
| N/A | $16.8m | Series E | |
| N/A | $2.1m | Debt | |
$25.0m | Debt | ||
| N/A | $23.0m | Series F | |
| N/A | $6.6m | Late VC | |
$22.6m | Late VC | ||
| N/A | N/A | IPO | |
$27.2m | Post IPO Debt | ||
| Total Funding | CAD180m | ||
Related Content
Recent News about Exagen Diagnostics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.